Highest-materiality recent filing
Artivion Q2 2026 revenue $125.8M (+11% YoY); net loss $(13.5M) vs prior year net income
Revenue $125.8M, up 11% GAAP (9% constant currency) YoY; net loss $(13.5M) or $(0.28)/share vs net income $1.3M in Q2 2025.
Artivion completes $135M acquisition of Endospan; adds Nexus aortic stent graft
Net purchase price of $135M funded via $150M delayed draw term loan.
Artivion Q1 rev $116M, net income $1.4M; lowers FY outlook; exercises Endospan option for ~$135M net
Q1 revenue $116.3M (+18% GAAP, +12% constant currency YoY); net income $1.4M ($0.03 diluted EPS) vs net loss $0.5M in Q1 2025.
Artivion Q4 revenue $116M (+19%), GAAP net income $2.4M; full year $441M
GAAP revenue Q4 $116.0M vs $97.3M, net income $2.4M ($0.05 diluted EPS) vs net loss $16.5M in Q4 2024.
Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance
Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.
Artivion extends credit facility maturities to 2031, adds $150M delayed draw term loan
Maturity of existing term loans and revolving credit facility extended to January 18, 2031.
Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance
Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.
Artivion exchanges $99.5M of convertible notes for 4.3M shares; nearly eliminates 2025 debt
Exchanged $99.54M principal of 4.250% convertibles due 2025 for 4,334,347 shares of common stock.
Artivion agrees to exchange ~$95M of 2025 convertible notes for common stock
Enters private exchange agreements with holders of 4.250% convertible notes due July 2025; ~$94.54M principal to be exchanged for shares.
Artivion Q1 revenue $99M (+2% GAAP), net loss $0.5M; raises FY 2025 guidance
Revenue $99.0M, up 2% GAAP (4% constant currency); net loss $(0.5)M vs net income $7.5M in Q1 2024.
Artivion Q4 revenue $97.3M (+4% YoY); FY2025 revenue guidance $420-435M
Q4 revenue $97.3M (+4% GAAP, +3% constant currency); On-X, stent grafts, BioGlue each grew 8-10%.
Artivion reports cybersecurity incident discovered Nov 21; systems taken offline
Incident involved acquisition and encryption of files; external advisors engaged.
Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M
Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.
Artivion Q2 revenue $98M (+10% YoY), narrows net loss, raises FY24 guidance
Revenue $98.0M (+10% GAAP and constant currency); net loss ($2.1M) vs ($3.4M) YoY.
Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net
Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.
Artivion Q1 revenue $97.4M (+17% YoY); nets $7.5M income vs loss; raises FY24 guidance
Revenue $97.4M, up 17% GAAP (16% constant currency) vs $83.2M in Q1 2023.
Artivion Q4 revenue $93.7M (+18% YoY); guides 2024 rev $382-396M
Q4 revenue $93.7M (+18% GAAP, +15% constant currency); full year $354.0M (+13%).
Artivion enters $350M credit facility with Ares Capital, refinances existing debt
Entered $350M credit facility: $190M initial term loan, $100M delayed draw term loan, $60M revolving credit facility.
Artivion appoints Lance A. Berry as CFO; Ashley Lee to retire after nearly 30 years
D. Ashley Lee, EVP & CFO, retires effective Dec 31, 2023; will serve as consultant for 1 year.
Artivion Q3 revenue $87.9M (+14% YoY); raises FY2023 revenue and EBITDA guidance
Revenue $87.9M, up 14% GAAP and 12% constant currency vs Q3 2022; net loss ($9.8M) or ($0.24)/share.
Artivion Q2 revenue $89.3M (+11% YoY); raises FY revenue guidance to $342-350M
Net loss ($3.4M) or ($0.08)/share; non-GAAP net income $2.3M ($0.06)/share.
Artivion Q1 revenue $83.2M (+8% GAAP, +10% constant currency); raises FY guidance
Net loss ($13.5M) or ($0.33)/share; non-GAAP net income $769k ($0.02)/share.
Artivion Q4 GAAP EPS $0.05 vs ($0.51) loss; 2023 revenue outlook $331M-$343M
Q4 revenue $79.4M, flat GAAP, +5% constant currency; On-X +11% CC, aortic stent grafts +16% CC.
Artivion Q3 revenue $76.8M (+6% GAAP, +11% constant currency); net loss $0.34/share
Revenue $76.8M, up 6% GAAP and 11% constant currency vs Q3 2021.
Artivion stops PROACT Xa trial; apixaban fails non-inferiority vs warfarin for On-X aortic valves
DSMB recommended stopping PROACT Xa due to lack of evidence supporting non-inferiority of apixaban to warfarin.
Artivion Q2 revenue $80.3M (+6% GAAP, +9% CC); net loss widens to $4.3M
Revenue $80.3M vs $76.1M YoY; constant currency growth of 9%.
Artivion Q1 revenue up 8.6% to $77.2M; net loss of $0.08 per share
Revenue $77.2M, +8.6% GAAP YoY; constant currency growth 11.2% driven by aortic stent grafts (+34%) and On-X (+11%).
Artivion Q4 revenue record $79.4M (+16.9%), net loss widens to $20.1M; guides 2022 rev $319-325M
Q4 revenue $79.4M, up 16.9% GAAP; net loss ($20.1M) vs ($3.5M) in prior year.
CryoLife Q3 revenue $72.2M (+11% YoY); net income $10.6M; non-GAAP EPS ($0.03)
Revenue $72.2M, up 11% GAAP and 9% constant currency vs Q3 2020.
CryoLife sells PerClot to Baxter for up to $60.8M; Q2 revenue up 42% to $76.1M
Total consideration up to $60.8M: $25M at closing ($19M to CryoLife), $25M upon FDA PMA approval, $10M sales milestones.
On December 4, 2023, D. Ashley Lee, the Executive Vice President, Chief Financial Officer and Treasurer of Artivion, Inc. (the “Company”), notified the Company of his decision to retire effective December 31, 2023 (the “Retirement Date”).
On December 4, 2023, the Company’s Board of Directors appointed Lance A. Berry as the Company’s Chief Financial Officer and Treasurer, effective as of that date.
increased the size of the Board to nine directors and appointed Elizabeth A. Hoff as a director and a member of the Compliance Committee of the Board, effective October 1, 2022.
on September 20, 2021, the Board of Directors (the “Board”) of CryoLife, Inc. (the “Company”) appointed Anthony B. Semedo as a director and a member of the Compliance Committee of the Board, effective on October 1, 2021.
the Company was informed on September 20, 2021 that Ronald D. McCall, Esq., a director of the Company since January 1984 and Presiding Director from December 2005 to March 2021, unexpectedly passed away.
Max materiality 0.85 · Median 0.68 · Most common event earnings